We will see soon enough. Thursday when Sanofi reports the real Script numbers and we can start to estimate an accurate growth rate, we will begin to trend up. Shorts will start to cover and this will hit $10 very quickly.
Lines are ready to rock and roll, just need more sales.
$3 strike against a pps of 5.75. $2.75 of the $2.90 is already baked in the price. you are paying a premium of .15c to .25c depending on your purchase price. Way too cheap right now. Take advantage of price mis-matches when they occur.
Paying less that .25c for over a year of time. Looks at least $1 low to me.
Shorts are struggling to find shares. No one is selling down here. Covering is getting harder and harder. As script refills begin to ramp up as well as new scripts being filled we will see a few months of large jumps in total scripts.
Loans get paid back every month at BCDs as large as PSEC. They can either make new loans with that money or buy back shares. Payback or earnings on new loans is 3 to 10%. Instant 27% for share buybacks which in turn drives up earning per share. If the discount to NAV was say 15%, I would want them to continue to make loans and increase earnings per share that way. But with this huge discount to NAV, share buybacks make more sense.
The article was written by an ex owner of shares. He only looked at the last couple quarters for expenses. We know ACAS took some huge costs for reducing head count and that expenses should be trending down quickly. I would not change my position based on his article, we need to see what effect the cost reductions had first. The 5th will be pivotal for ACAS share price. I am expecting price to jump up.
I do not understand all the chatter about a buy out. The only people who benefit from that are the buyers. 3 to 5 yrs from now MannKind will be a $300 stock, real investors are not hoping for a buy out at this reduced price. I do not want a buy out, I want prescription growth.
Current capacity can handle over $1B in sales. When Mannkind starts reporting earnings pushing $300Million, they had better be expanding manufacturing and packaging, until then, they have enough capacity.
You cannot value a company growing sales by 20% -25% per week which is why most startup pharma and biotech companies trade for astronomical valuations when they start to break even. Mannkind will be no different. In a few short months we should be trading in the teens.
The trend is our friend. Hold on as the catalysts from ADA and DTC are not yet being felt. I predict a couple thousand scripts per week by Sept.
Shorting a company paying a 13% div is not wise and most shorts will jump in and jump out not hold long term due to paying that div. Now that the bashers have finished pushing the stock down, all the shorts will run for cover.
His article displaces most of the non-facts that have been spread recently about PSEC and the management. A good read. He is looking for a short squeeze as am I.
They were fine on the call. Mannkind is a pharma company, not a social media company. They addressed the questions and provided some clarity. Started working on 1rst Techno product, 18 to 24 months est completion. Ramping up marketing to doctors. DTC in a few weeks will start. Tier 2 and Tier 3 status making progress. Meeting in two weeks with Sanofi about which countries they will work toward approval of Afrezza next, we could hear about this in the next QTR earnings and this will be huge. They feel all the remaining milestone payments are achievable, most are sales orientated but also launch in other countries and manufacturing ramp up.
I left the call feeling pretty darn good about my investment in Mannkind. I am not looking for a quick flip here, long term holder. The company and SNY are executing their plan and making progress. When the results start to show the share price will appreciate. Long and strong.
Did not say nothing happens for 12 to 18 months. He said API is arriving this week, so they are definitely working on it. Bringing a new product to market is not like baking cookies from a package. The scientist need time to perfect it. But product #1 is underway.